|Bid||225.32 x 800|
|Ask||232.35 x 1300|
|Day's Range||228.14 - 231.98|
|52 Week Range||216.12 - 388.67|
|Beta (3Y Monthly)||1.73|
|PE Ratio (TTM)||9.91|
|Earnings Date||Jul 22, 2019 - Jul 26, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||261.62|
Wayfair, the Boston-based online furniture retailer, joined the ranks of Massachusetts businesses with a spot on Fortune magazine’s list of 500 of the highest-grossing companies in the United States.
The drug development pipelines of Gilead Sciences, Amgen and Biogen are running thin, and the companies might need to M&A to get going again, according to JPMorgan.
The Chinese e-commerce giant beat estimates by a wide margin on both the top and bottom lines, driven both by increased user engagement and growth in its cloud business. Tilray TLRY — Tilray reported an adjusted quarterly loss of 27 cents per share, two cents larger than analysts were expecting. The Canadian marijuana producer's revenue did come in above estimates, helped by acquisitions, legalization of recreational marijuana use in Canada and growth in its medical markets.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on May 14) Arena Pharmaceuticals, Inc. (NASDAQ: ARNA ) Avedro Inc ...
England's National Health Service said it had reached a deal to pay for U.S. drugmaker Biogen Inc's expensive spinal muscle atrophy treatment Spinraza. NHS England said it reached a "managed access agreement" with Biogen under which it will fund treatment for a limited time and collect data on the drug's effectiveness. NHS England did not disclose the price it will pay for the drug.
Biogen Inc. (BIIB) today announced that The National Institute for Health and Care Excellence (NICE) in the United Kingdom has recommended funding for SPINRAZA (nusinersen) on the National Health Service (NHS). The positive recommendation is for the treatment of infants, children and adults with 5q spinal muscular atrophy (SMA), including pre-symptomatic and symptomatic SMA Types 1, 2 and 3.
Dr. Reddy's (RDY) will provide updates on new generic filings and new drug applications, when it reports fourth-quarter fiscal 2019 results.
WOODCLIFF LAKE, N.J., May 13, 2019 /PRNewswire/ -- The Alzheimer's Clinical Trials Consortium (ACTC) and Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that the investigational oral BACE (beta amyloid cleaving enzyme) inhibitor elenbecestat (development code: E2609) and the investigational anti-amyloid beta (Ab) protofibril antibody BAN2401, which are currently being evaluated as treatments for early Alzheimer's disease (AD), have been selected by the ACTC as treatments to be evaluated in upcoming clinical studies targeting primary prevention (A3 Study) and secondary prevention (A45 Study) of AD.
PDL BioPharma's (PDLI) earnings exceed estimates in the first quarter of 2019. Higher royalty rights as well as product sales lead to a marginal spurt in year-over-year revenues
The Parnassus Endeavor Fund (Trades, Portfolio) bought shares of the following stocks during the first quarter. Warning! GuruFocus has detected 4 Warning Signs with ABBV. The fund established a stake in AbbVie Inc. (ABBV), buying 1.7 million shares.
The Fed made a material reversal at year-end and lower interest rates have fueled gains for both stocks and bonds. Unprecedented technological innovation is driving impressive productivity gains which has helped to keep inflation in check. Where socialism grows so does inflation and stagnation.
Let's take a sneak peek at some ETFs having high exposure to some impactful biotechnological companies on the release of Q1 earnings results.
PTC Therapeutics and Roche's spinal muscular atrophy treatment showed positive test results early Tuesday — leading shares of rival Ionis Pharmaceuticals and Biogen to slide.
Biogen Inc NASDAQ/NGS:BIIBView full report here! Summary * ETFs holding this stock have seen outflows over the last one-month * Bearish sentiment is low * Economic output in this company's sector is expanding Bearish sentimentShort interest | PositiveShort interest is extremely low for BIIB with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting BIIB. Money flowETF/Index ownership | NegativeETF activity is negative. Over the last one-month, outflows of investor capital in ETFs holding BIIB totaled $2.15 billion. Additionally, the rate of outflows appears to be accelerating. Economic sentimentPMI by IHS Markit | PositiveAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, and is accelerating. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to email@example.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
Biogen Inc. (BIIB) presented new data illustrating its ongoing commitment to improving care for people living with multiple sclerosis (MS) at the 71st annual meeting of the American Academy of Neurology (AAN) in Philadelphia (May 4–11). Data support the well-established therapies within Biogen’s leading MS portfolio, TECFIDERA® (dimethyl fumarate) and TYSABRI® (natalizumab).
Some chief executive officers were stepping up to the buy window as well. Conventional wisdom says that insiders and 10 percent owners really only buy shares of a company for one reason -- they believe the stock price will rise and they want to profit from it. Biogen Inc (NASDAQ: BIIB) CEO Michel Vounatsos and a director last week acquired a total of nearly 122,700 shares of this noted biotech company.